HealthPolitics

STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 30/10/2026, 08:36:24 UTC.

Briefings

The Trump administration launched new payment and regulatory pathways to reduce friction for health AI developers. However, states and the federal government have overlapping jurisdiction over AI performing clinical tasks like prescribing medications, creating a potential regulatory conflict that could push such products into FDA oversight. The article notes ongoing efforts to boost AI adoption in healthcare but highlights the unresolved jurisdictional tension.

Key points

• The Trump administration introduced new payment mechanisms and regulatory frameworks designed to lower barriers for developing health AI technologies.
• States and the federal government share overlapping jurisdiction over AI performing clinical tasks, such as writing prescriptions, which may lead to regulatory conflicts.

Context

Health officials are actively working behind the scenes to resolve conflicts between state and federal authorities regarding AI adoption in clinical settings.

Limitations

Evidence is limited to the article's summary of the administration's actions and the stated jurisdictional overlap. Specific dates, state names, or numbers are not provided. The article does not contain data on adoption rates, financial costs, or specific regulatory outcomes.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 30/10/2026, 09:49:08 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidyb5yxgrgnoa5dbguoo52pqarks74pipjfvgddfxkxixhn3chuhy